公开(公告)号：US12186318B2

公开(公告)日：2025-01-07

申请号：US17083895

申请日：2020-10-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyung Jun Ahn

IPC: A61K31/517 ,  A61K31/337 ,  A61K31/404 ,  C12N15/113 ,  A61K45/06

Abstract: The present invention relates to a method of treating a cancer including administering a pharmaceutical composition to an individual suspected to have the cancer excluding humans in a pharmaceutically effective amount, where the pharmaceutical composition comprises an agent capable of inhibiting expression of kinesin spindle protein (KSP) and a mitosis inhibitor.

公开(公告)号：US10266820B2

公开(公告)日：2019-04-23

申请号：US14754556

申请日：2015-06-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyung Jun Ahn ,  Ick Chan Kwon ,  Mihue Jang ,  Jong Hwan Kim

IPC: C12N15/11

Abstract: A RNA/DNA nanoparticle for delivering siRNA where a RNA transcript including at least one hairpin structure hybridizes DNA-cholesterol conjugate and folate-DNA conjugate including a complementary sequence to the RNA transcript, and a composition including the RNA/DNA nanoparticle is provided. More specifically, because various siRNA used for different applications can be contained in the RNA/DNA nanoparticle for delivering siRNA at a high loading efficiency, and has stability to the outer attacks such as nuclease degradation. The RNA/DNA nanoparticle siRNA can be prepared by self-assembly without using polycationic agent which is harmful agent for body. The folate targeting to various cancer cells can accumulate the nanoparticle selectively on target cancer cell after intravenous injection, and make excellent gene-silencing effect inside the cancer tissue, thereby being used as a good agent for treating cancers.

公开(公告)号：US20200046753A1

公开(公告)日：2020-02-13

申请号：US16199815

申请日：2018-11-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyung Jun Ahn ,  Seo Young Kwak

IPC: A61K31/7105 ,  C12N15/113 ,  A61K9/127 ,  A61K31/221 ,  A61K48/00 ,  A61P35/00

Abstract: The present invention relates to a composition for nucleus-independent, sustained inhibition of gene expression, comprising an mRNA fragment of T7 RNA polymerase, plasmid DNA for self-amplification of the T7 RNA polymerase, and a DNA fragment encoding a gene expression inhibitor; a transporter of the gene expression inhibitor comprising the composition; and a method of preparing the transporter.The composition of the present invention and the liposome transporter of the present invention comprising the composition can improve the expression of shRNA in the cytoplasm through self-amplification of nucleus-independent, sustained self-amplification of T7 RNA polymerase, and deliver them in a cancer tissue-specific manner. Therefore, the composition and the liposome transporter of the present invention can be utilized for use in treating chronic diseases that require reduced frequency of administration and long-term inhibition of gene expression.

公开(公告)号：US11498976B2

公开(公告)日：2022-11-15

申请号：US16878672

申请日：2020-05-20

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyung Jun Ahn ,  Sungjin Lee

IPC: C07H21/04 ,  C07K16/30 ,  A61P35/00 ,  C12N15/86

Abstract: The present invention relates to a viral complex comprising a viral vector capable of delivering shRNA that suppresses an expression of epidermal growth factor receptor (EGFR) to a cell and an anti-epithelial cell adhesion molecule (EpCAM) antibody conjugated to the viral vector, a pharmaceutical composition for preventing or treating cancer, comprising the viral complex, and a method for treating cancer, comprising administering the viral complex or the pharmaceutical composition to a subject in which a cancer disease has occurred and overexpressing EpCAM. The anti-EpCAM antibody-AAV2/shEGFR complex provided in the present invention significantly reduces the expression level of EGFR in tumor cells overexpressing EpCAM without inducing an immune response in vivo, thereby inducing death of tumor cells, and thus, it can be widely utilized in more effective and safe cancer treatment.